Episode 440: The Hidden Benefits of GLP-1s: More Than Just Weight Loss Medication

Hi guys, it's Tony Robbins. You're listening to Habits and Hustle.
Crush it.

Are there hidden benefits to GLP-1s that the FDA just isn't talking about? In this Fitness Friday episode of Habits and Hustle, I sit down with Dr. Tina Moore to break down the truth about GLP-1 medications and the hype surrounding them.
Dr. Tina is an expert in holistic regenerative medicine.
She shares why these drugs are more than just weight loss tools and how the conversation

around them has become very polarizing. This is a short clip from our full interview where you

can find the full episode linked in the show notes below. Please listen and comment with anything you'd like.
Enjoy the episode. Before we jump into today's interview, a quick word from our sponsor, Biome.
Did you know 95% of us aren't getting enough fiber? That's a big deal because fiber is key to our gut health, digestion, energy, and even our weight management. And that's why I'm excited to share Biome's daily prebiotic fiber with you.
It has eight grams of fiber per serving plus prebiotics to support your gut. It's an easy and tasty way to close that fiber gap in your diet.
You can mix it into smoothies or yogurt. There's flavors like chocolate or unflavored versions.
It's both simple and enjoyable. And I love how easy it is to fit into your busy routine.
And it's perfect for when you travel as well, which is why I always take it with me in my bag. If you want to make fiber a part of your daily routine, and I suggest you do, head to bio.me and use code JENNIFER20 for 20% off your first order.
That's B-I-O dot M-E and code JENNIFER20 for 20% off. Now let's dive into today's episode.
There's so much controversy over Ozempic, right? Like most people are like, oh, you know what? Like it's like the easy way out. You're not learning, you know, behavioral differences or habits.
You're just kind of taking a shot to lose weight. And you are on the opposite side of the fence, right? You actually, you're a big proponent of using these drugs.
Well, I'm talking, I was originally about a year ago, I found all this data and literature, like 20 years of studies, showing that this class of, they're peptides for one, they just happen to be owned by Big Pharma. Can you talk about what it is? Because I think no one really understands, is it a peptide? Is it a drug? Let's start with what GLP-1 is.
It's a peptide. So it's a string of amino acids linked together by peptide bonds.
So it's a peptide. We make GLP-1 in our bodies naturally, in our brain and in our guts.
We have receptors for GLP-1s all over our body that do a whole lot of different things. It just was serendipitous that it got figured out for type 2 diabetes.
It does a whole lot of other things in the body. And this was really interesting to me when I started studying it.
It's a peptide in that it's in and out of the body very quickly. So the body produces it and the half-life is very short.
The pharmaceutical version has been tinkered with so that the half-life is much longer. So the half-life is maybe four to seven days.
So that's it. It's bioidentical, at least Ozempic, which is semaclutide, is bioidentical to our own GLP-1 for the most part.
And about a year ago, I started finding literature outside of what most people understand it for. Most people understand it for reducing appetite because it plays on the centers of our brain that control appetite, for slowing gut motility so you feel fuller longer.
And that's kind of where the story ends. That's kind of where people understood how it works, and that's why it's a weight loss drug, and that's why it's for type 2 diabetes.
It has multiple impacts on our metabolic health in a myriad of ways that have a lot more to do than just that. And there are receptors in our brains, in our heart, in our pancreas, in our immune cells.
And I started finding literature that was really, really interesting about this. And I started going on podcasts and sharing about it and finding information like recent studies have come out showing significant reduction in all-cause mortality for those who are on it, reduction in different types of cancers.
Cancers? Colon cancer specifically. This was correlative, not causative, but they were finding, they were comparing people on somaclutide versus, or even some of the other GLP ones for a period of time versus, I think, insulin.
And not a great, I mean, it's not a super clear comparison because insulin is pro-grow, so insulin can cause problems in and of itself. But interesting data coming out there recently, 13 different types of, potentially reducing 13 different types of obesity-related cancers.
And then I was finding data and sharing out about potential protection against COVID and upper respiratory illness. And I was sharing about it on podcasts thinking, well, if anything, I'm helping big pharma sell their peptides, so they'll probably leave me alone.
Like I didn't think I was a threat there, you know? And honestly, the microdose is completely independent to the individual sitting in front of me. And that person, for that person, it might be the standard standard starting dose.
That might be their microdose, right? So I have no idea. But then I started a second account a few days later, and it grew to 15,000 followers pretty quickly.
And it was shut down within 36 hours. And that's when I realized, oh, somebody wants me to shut up.
Right, right, right. Well, I mean, if you're trying to take business away, who makes Ozempic? Who's the company that makes Ozempic? Novo Nordisk.
And then Monjoro is Trisepetide, and that's Eli Lilly. And so I, but I mean, I have no interest in keeping people away from the standard.
I don't care. What's interesting is when I started talking about this, I was like, you guys, I'm finding all this amazing literature supporting GLP-1s for neuroregeneration and decreases in inflammation and neural inflammation, which I think is really cool.
That's where I got most interested. And potential, there's studies being done right now on potential improvements in Alzheimer's and Parkinson's.
And like, this is super exciting, guys. And my followers, so many of them turned on me and they're like, when did you get, they were like, when did you get bought out by Big Pharma? When did you become a Big Pharma shill? So they're screaming at me in my comment section, accusing me of being a Big Pharma shill.
And I'm like, no, I'm talking about compounded versions, you guys. I'm not even talking about the standard brand name.
But if you want to use the standard, great.

And many of the people that I talked to in my following have said, you know, I could only get a hold of the standard brand name through my regular doctor, through regular pharmacy. And it's changed my life.
So I'm like, cool. You know, I don't have any favoritism either way.
Right. I'm just saying that if for someone like you, as lean as you are and metabolically optimized as you are, if you had maybe cardiovascular disease in your family or you were dealing with some kind of neurodegenerative condition, we would need tiny, tiny doses for you.
So wait, like, so, so yeah, that's what's interesting. So in your opinion, should everybody be on one of these GLP-1, like an endozampic form for their metabolic health? I think that I get asked that a lot.
I think that's kind of a bold statement to make, and I wouldn't say yes to that. I think the way that I've always practiced medicine is I'm just trying to treat the person in front of me, and I'm trying.
I don't use this in isolation. It's not a monotherapy.
It's part of a comprehensive protocol. So I'm a big fan of bioidentical hormone replacement.
I've been using it in practice for a long time. My background was actually as a regenerative medicine doctor.
So I was doing prolotherapy, PRP, stem cells, exosomes, regenerative therapies in my clinic for decades. So to me, peptides are just part of that.
And this is just another peptide. But where do peptides even come from? I feel like